Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 14/20 | 0.67 |
| ▸ | NOS1 | P29475 | 12/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | NOS3 | P29474 | 9/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623779 | 1.00 | NOS2 (0.67) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL29798899 | 1.00 | NOS2 (0.67) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL4863062 | 0.84 | NOS2 (0.57) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL2981397 | 0.84 | NOS2 (0.48) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL5033970 | 0.84 | NOS2 (0.67) | NOS2NOS1CYP2C9NOS3 | |
| SCHEMBL4662911 | 0.84 | NOS2 (0.58) | NOS2NOS1CYP2C9NOS3NPC1 | |
| SCHEMBL5036979 | 0.83 | NOS2 (0.55) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL5036437 | 0.83 | NOS2 (0.58) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL5041184 | 0.82 | NOS2 (0.69) | NOS2NOS1CYP2C9NOS3SMN1; SMN2 | |
| SCHEMBL2835954 | 0.82 | NOS2 (0.54) | NOS2NOS1CYP2C9NOS3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490366-B1 | ALKOXYPYRIDINE-DERIVATIVES | NYCOMED GMBH (DE) | 2008-01-23 | — | — | EP | claimed |
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | claimed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | claimed |
| EP-1490366-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA Pharma AG (DE) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080607-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2003-10-02 | — | — | WO | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-1490366-B1 | ALKOXYPYRIDINE-DERIVATIVES | NYCOMED GMBH (DE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007041842-A1 | AN INFLAMMATORY MEDIATOR OF CARDIAC ADRENERGIC DYSFUNCTION | UNIVERSITY OF MANITOBA (CA) | 2007-04-19 | — | — | WO | disclosed |
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1490366-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA Pharma AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080607-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NOS2 2500/4885NOS1 2128/4885CYP2C9 3111/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | NOS2 856/4885NOS1 437/4885CYP2C9 235/4885 |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | NOS2, PNP, PTGIS | NOS2 1/4885NOS1 4/4885CYP2C9 304/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | NOS2 1676/4885NOS1 3082/4885CYP2C9 1982/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | NOS2 2500/4885NOS1 2128/4885CYP2C9 3111/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | NOS2 4326/4885NOS1 4381/4885CYP2C9 4482/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | NOS2 1676/4885NOS1 3082/4885CYP2C9 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.